Febrile neutropenia is one of the most serious toxicities of chemotherapy, with a reported mortality of 2% to 21% [1]. Guidelines define it by fever together with a neutrophil count below 0.5 x 10^9/L, or one expected to fall below that level, with minor differences in the temperature thresholds used [2, 3]. In practice, the decision to treat should not wait for a count: a patient who is unwell within weeks of myelosuppressive chemotherapy is treated as having neutropenic sepsis until proved otherwise.
Fever may be absent. Steroids, paracetamol and older age blunt it, and some patients present only with rigors, hypotension, confusion or a fall. The chemotherapy regimen and the date of the last cycle are the most useful facts in the referral.